论文部分内容阅读
目的:评估CT引导下n 125I粒子植入术治疗晚期胰腺癌的临床价值。n 方法:回顾性分析2015年6月至2018年6月郑州大学附属肿瘤医院63例晚期胰腺癌的患者资料（男48例，女15例），所有患者均在CT引导下行n 125I粒子植入术，术后定期随访资料完整。所有患者随访3~36个月，评估临床疗效，包括比较治疗前后癌肿体积、肿瘤标志物CA199及腹痛、黄疸等并发症变化情况，记录患者生存状况。n 结果:63例患者粒子植入术后3个月癌肿完全缓解9例（14.3%），部分缓解33例（52.4%），稳定15例（23.8%），疾病进展6例（9.5%），总有效率为67.7%。治疗后3个月癌肿体积（31.92±14.93）cmn 3较治疗前（44.88±16.19）cmn 3显著性减小（n t=6.79，n P<0.01）。治疗后3个月血清CA199（77.21±58.69）U/ml较治疗前（327.76±110.42）U/ml显著性降低（n t=16.56，n P<0.05）。n 125I粒子植入治疗晚期胰腺癌平均生存期（13.04±0.92）个月，中位生产期11个月。57例腹痛症状患者中49例较前好转，疼痛缓解率为85.9%。42例黄疸症状患者中31例较前好转，黄疸缓解率为73.8%。所有患者均未发生与治疗相关的严重并发症。n 结论:125I粒子植入治疗可安全、有效地治疗晚期胰腺癌，缓解腹痛、黄疸等相关临床症状。n “,”Objective:To evaluate the clinical value of n 125I seed implantation guided by CT in treatment of advanced pancreatic cancer.n Methods:The data of 63 patients with advanced pancreatic cancer in the Affiliated Cancer Hospital of Zhengzhou University from Jun. 2015 to Jun. 2018 (48 males and 15 females) were retrospectively analyzed. All patients underwent CT-guided n 125I seed implantation, and regular follow-up after operation. All patients were followed up for 3 to 36 months to evaluate the clinical efficacy, including the volume of cancer before and after treatment, tumor marker CA199 and changes in complications such as abdominal pain and jaundice, and the survival status of the patients.n Results:Three months after seed implantation, 9 cases (14.3%) had complete remission of cancer in 63 patients, 33 cases had partial remission (52.4%) , 15 cases had no change (23.8%) , and 6 cases had disease progression (9.5%) . The total effective rate was 67.7%. Three months after treatment, the volume of cancer was (31.92±14.93) cmn 3, which was significantly smaller than that before treatment [ (44.88±16.19) cmn 3; n t=6.79, n P<0.01]. Three months after treatment, Serum CA199 (77.21±58.69 U/ml) was significantly lower than that before treatment (327.76±110.42) U/ml (n t=16.56, n P<0.05) . n 125I seed implantation for advanced pancreatic cancer had an average survival period of (13.04±0.92) months and a median delivery period of 11 months. Of the 57 patients with different degrees of abdominal pain, 49 were better than before, and the pain relief rate was 85.9%. Among 42 patients with jaundice symptoms of varying degrees, 31 were better than before, and the jaundice remission rate was 73.8%. There were no serious complications related to treatment in any patients.n Conclusion:125I seed implantation therapy can safely and effectively treat advanced pancreatic cancer, and improve related clinical symptoms such as abdominal pain and jaundice.n